MedTrace Logo

MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)

NCT03078374 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-08-04

No results posted yet for this study

Summary

The purpose of this study is to obtain single-center safety and feasibility data on patients managed with reduced anti-coagulation, and the incidence of thrombotic and bleeding adverse events associated with the HeartMate 3 LVAS therapy.

Conditions

Interventions

DRUG

Warfarin

Reduced dosage to obtain lower INR range

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Institute for Clinical and Experimental Medicine

    lead OTHER_GOV

Principal Investigators

  • Ivan Netuka, MD, Ph.D. · Institute for Clinical and Experimental Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-11
Primary Completion
2022-01-31
Completion
2022-10-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03078374 on ClinicalTrials.gov